The 2nd Annual Pain Therapeutics Summit EUROPE is coming back in 2027Amsterdam, the Netherlands | April 5-6, 2027

The Pain Therapeutics Summit brings together professionals from across the pain research and drug development ecosystem, including biotechnology and pharmaceutical companies, academic researchers, clinicians, CROs, regulatory experts, NIH and government researchers, investors, translational scientists, and patient-focused organizations. Attendees range from early-stage discovery scientists to senior executives involved in clinical development, regulatory affairs, translational medicine, business development, and commercialization.

Yes. A major focus of the summit is the development of safe, effective, and non-addictive approaches to pain management. Sessions frequently cover non-opioid therapeutics, novel mechanisms of action, biologics, neuromodulation, biomarkers, translational science, clinical trial design, and emerging technologies aimed at advancing alternatives to traditional opioid-based therapies. The event also examines broader issues in pain therapeutics development, including regulatory strategy, patient stratification, and clinical outcomes research. See the Agenda

Yes. The summit regularly features participation from researchers and program leaders affiliated with the National Institutes of Health, including individuals involved with the NIH HEAL Initiative and related translational pain research programs. Recent programs have included speakers associated with the HEAL Pain Therapeutics Development Program (PTDP), which supports development of non-addictive pain therapeutics.

Absolutely. The summit is highly relevant for CROs involved in preclinical research, translational science, biomarker development, toxicology, clinical trials, regulatory support, data analytics, and commercialization strategy. Many attending organizations are actively seeking partners and service providers that can support pain therapeutics development programs from discovery through clinical development. Request Sponsorship Details

The conference covers a broad range of pain-related therapeutic areas and indications, including neuropathic pain, inflammatory pain, osteoarthritis, migraine, musculoskeletal disorders, cancer pain, visceral pain, rare disease-associated pain, acute pain, chronic pain, and pain associated with neurological disorders. The agenda also explores emerging approaches involving biomarkers, precision medicine, neuromodulation, biologics, AI-enabled drug development, and translational research.

Yes. Networking and collaboration are central components of the summit. The event includes networking breaks, meals, receptions, and informal meeting opportunities designed to facilitate discussions between industry, academia, CROs, investors, clinicians, and government stakeholders. Many attendees use the event to explore research collaborations, licensing opportunities, strategic partnerships, and business development discussions.

Yes. The summit welcomes scientific poster presentations from academic researchers, industry scientists, clinicians, postdoctoral fellows, and students. Poster sessions are designed to highlight emerging research, foster discussion, and provide additional networking opportunities for presenters and attendees alike. Poster Session Details

The summit typically attracts biotechnology companies, pharmaceutical firms, CROs, contract manufacturing organizations, academic medical centers, government agencies, consulting firms, investors, technology providers, and research institutions involved in pain therapeutics and translational medicine. Attending organizations often span early-stage startups through large multinational pharmaceutical companies, as well as NIH-supported research programs and translational development initiatives.